On Nov. 2, AMCP joined a pharmacy stakeholder coalition letter to CMS requesting the agency use its PREP Act authority to establish payment mechanisms for Medicare and Medicaid to reimburse pharmacists for COVID-19 patient assessment services.
On Oct. 28, AMCP joined a pharmacy stakeholder coalition letter to HHS requesting authorizations for pharmacists, pharmacy technicians and interns to order and administer antiviral medications and flu tests.
In October, AMCP joined other pharmacy organizations in supporting the Pharmacist's Fundamental Responsibilities and Rights released by APhA and the National Alliance of State Pharmacy Associations (NASPA). These principles focus on pharmacists' responsibilities and the workplace conditions necessary to fulfill those responsibilities.
AMCP submitted comments on the proposed FDA Prescription Drug User Fee Act Reauthorization commitment letter, supporting the agency's plans to increase resources for approval of cell and gene therapies and continued exploration of uses for real-world evidence in regulatory decision-making.
On Sept. 14, AMCP joined a Medicaid stakeholder letter urging Congress to include language that requires 12-month continuous eligibility for children on Medicaid and the Children’s Health Insurance Program (CHIP) in the reconciliation bill.
Letter requests an immediate amendment to the PREP Act declaration on COVID-19, which would allow pharmacists to order and administer REGEN-COV and future authorized products for the treatment of COVID-19.
On July 28, AMCP signed a Medicare Part D stakeholder letter urging HHS to extend the Enhanced Medication Therapy Management (EMTM) Model which is currently set to expire on December 31, 2021.
On July 26, AMCP joined other health care organizations in a joint statement in support of COVID-19 Vaccine mandates for all workers in health and long-term care.
AMCP submitted comments on a Office of Management and Budget request for information on advancing equity in underserved communities through government.
On June 14, AMCP submitted comments on the Medicare Part D Medication Therapy Management Program's Standardized Format for the comprehensive medication review.
On May 25, AMCP joined Medicare stakeholder organizations in thanking Congressional members for introducing the Pharmacy and Medically Underserved Areas Enhancement Act (H.R. 2759/S.1362).
On April 19, AMCP submitted joint recommendations to CMS on Medicare Advantage enrollees seeking COVID-19 vaccine without their Original Medicare card. CMS is recommended to present clear guidance to all vaccination sites and providers and instruct MACs to provide assistance to providers to ensure vaccine administration is accurately reimbursed and entered into the COVAX portal.
AMCP submitted a letter on the reopened comment period for the Medicaid Coverage of Innovative Technologies rule, which created a pathway for fast national Medicare coverage of innovative technologies, including digital therapeutics.
On March 16, AMCP joined Medicare stakeholders in urging House and Senate leadership to swiftly repeal the 2020 Medicare Part D rebate rule using Congressional Review Act authority.
On Feb. 18, AMCP joined the Modern Medicaid Alliance in urging Congress to strengthen the Medicaid program in the next COVID response bill by increasing the Federal Medical Assistance Percentage (FMAP) by at least 12 percentage points.
AMCP submitted comments to CMS on the Most Favored Nation Model rule, expressing our significant concerns that the model would negatively impact patient access to needed medications.